Related Experiment Videos
[The intraocular pressure lowering effect of human atrial peptide]
Insights
Human atrial natriuretic factor (hANF) significantly reduced high intraocular pressure (IOP) in glaucoma patients. This cardiovascular hormone shows potential as a novel antiglaucoma therapeutic agent.
Area of Science:
- Cardiovascular endocrinology
- Ophthalmology
- Nephrology
Context:
- Human atrial natriuretic factor (hANF) is a hormone regulating fluid and sodium balance.
- Receptors for hANF are present in ocular tissues, suggesting a role in intraocular pressure (IOP) regulation.
- Glaucoma is characterized by elevated IOP, posing a risk to optic nerve health.
Purpose:
- To investigate the effect of hANF on IOP in glaucoma patients.
- To determine if hANF can be a potential therapeutic agent for glaucoma.
Summary:
- hANF was administered intravenously to 10 glaucoma patients with elevated IOP (>33 mmHg).
- IOP was monitored for 8 hours post-injection.
- A significant reduction in IOP was observed after hANF administration.
Impact:
- hANF demonstrated a significant IOP-lowering effect in glaucoma patients.
- These findings suggest hANF's potential as a novel therapeutic agent for managing glaucoma.
- Further research into hANF's antiglaucoma properties is warranted.
Abstract:
The human atrial natriuretic factor (hANF) is a cardiovascular hormone, which promotes renal sodium secretion in response to increases in extracellular fluid volume and atrial pressure. It regulates sodium and volume homeostasis. Specific receptors for hANF have been identified in the ciliary processes of rats and rabbits, which mediated a long-lasting reduction in intraocular pressure (IOP) after intra-atrial injection. In a series of 10 glaucoma patients with bilateral IOP elevations above 33 mmHg an i.v. bolus injection of hANF was administered and IOP was recorded before and over an 8-h period after injection. The human atrial natriuretic factor lowered IOP significantly. The potential of hANF as an antiglaucoma agent is discussed.